MLYS Company Profile and Key Details

MLYS has shown weak momentum, losing -3.18% over the past week and -26.7% over the past quarter, though year-to-date performance is down -12.01%. Short-term trend indicators are mixed aligned (SMA20 -1.76%, SMA50 -11.11%, SMA200 2.65%). The stock’s 14-day RSI is 43.25 (neutral), while the ATR of 1.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -39.08% below its high and over 234.25% above its low. Average 10-day trading volume of 2.11 million shares is slightly above the 3-month average of 1.45 million, indicating heightened recent market interest.

Mineralys Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.56. This means the shares are trading above this model’s fair value.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) closed at $25.37 USD, gaining $0.74 (3.00%) from the previous close of $24.63. The stock is currently mid-range between its 52-week high and low $12.59 and $47.65. With a market capitalization of about $1.68 billion, Mineralys Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 1.49 million shares, in line with its 52-week average. Headquartered in Radnor, PA, Mineralys Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jon Congleton, the company employs approximately 51 people and listed since February 10, 2023. Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials.

Mineralys Therapeutics, Inc. has 66.30 million shares outstanding. The public float is 44.08 million shares, elevated short interest at 14.19% of float. This equals 7.00 million shares. The short ratio is 10.35 days. Institutional investors hold 114.54% of the float. Insiders own 0.72%. Slingsby Brian Taylor holds 7.90 million shares, RA CAPITAL MANAGEMENT, L.P. has 5.83 million shares and Samsara BioCapital GP, LLC has 5.67 million shares. Over the past six months, insider transactions show net selling. They sold 279.20 thousand shares across 33 transactions.

Mineralys Therapeutics, Inc. generated EPS of -$2.96 over the past year. Five-year average earnings growth is -170.42%. Wall Street analysts project EPS growth of 11.46% annually over the next five years. The latest quarter delivered EPS of -$0.47. The next quarter is forecast at -$0.52. Next year's EPS is expected at -$20.75. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $56.00 to $26.00. The high target offers 120.73% upside. The low target suggests 2.48% downside. The mean target is $47.36. This offers 86.68% upside. Mineralys Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 06, 2026, missed forecasts by -7.84%. The prior quarter beat by -22.52%. Over the last six quarters, Apple has recorded several small beats. These include -2.0% in February 12, 2025.

Mineralys Therapeutics, Inc. trades at a P/E ratio of -12.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.23 trading at moderately above to book value. The P/FCF stands at -12.08, also below market averages.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) shares are down -12.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mineralys Therapeutics, Inc. trading at a premium to the broader market with a P/E of -12.13. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.55, suggesting 59.83% upside. Our AI forecast model points to short-term weakness (-5.79% over two weeks), a medium-term rise (134.13% over three months), and a longer-term gain (32.05% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mineralys Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.79%, with price expected at $23.90 by July 06, 2026, within a range of $21.17 to $26.64 3-Month Outlook: Projected rise of 134.13%, reaching $59.40 by September 18, 2026, with a range of $58.43 to $60.50. 1-Year Outlook: Projected gain of 32.05%, with price at $33.50 by June 22, 2027, within a range of $31.44 to $36.32.